Dopamine

Dopamine is an organic chemical that acts as a neurotransmitter in the brain and as a hormone and local messenger elsewhere in the body. It belongs to the catecholamine family, which also includes norepinephrine and epinephrine, and it is built from the amino acid tyrosine through a short enzymatic pathway. Its importance comes from the range of functions it coordinates. In the brain it helps control voluntary movement, supports learning from rewards, sets the drive to pursue goals, and contributes to working memory and attention. Outside the brain it takes part in hormone regulation, kidney function, gut activity, and cardiovascular control. Because dopamine signalling is disrupted in Parkinson's disease, schizophrenia, attention-deficit/hyperactivity disorder, and addiction, it is also central to clinical medicine and to pharmacology.

This entry first covers what dopamine is at the level of chemistry, including its synthesis, storage, release, breakdown, and the receptors that transmit its signal inside target cells. It then turns to the anatomy of the main dopaminergic pathways and the functions they serve, focusing on movement, reward prediction and learning, and cognition. The entry next describes dopamine's peripheral and hormonal roles and the disorders that arise when its signalling is altered. It ends with the history of discovery, the Nobel-recognized work that established dopamine as a neurotransmitter, and the methods researchers use to measure and manipulate it.

Chemical structure and biosynthesis

Structure

Dopamine is a small organic molecule with a benzene ring that carries two adjacent hydroxyl groups, a motif called a catechol, and a two-carbon ethylamine side chain. Its formula is C8H11NO2. Because of this catechol group, dopamine belongs to the catecholamine family, which also includes norepinephrine and epinephrine, and these three compounds are products of one pathway and act as both hormones and neurotransmitters in the central and peripheral nervous systems. Norepinephrine differs from dopamine by one extra hydroxyl group on the side chain, and epinephrine adds a methyl group to the amine. Dopamine-β-hydroxylase converts dopamine to norepinephrine, and phenylethanolamine N-methyltransferase then methylates norepinephrine to form epinephrine.

Biosynthesis

Dopamine is made from the amino acid L-tyrosine in two enzymatic steps. The first is catalysed by tyrosine hydroxylase, which uses tetrahydrobiopterin and molecular oxygen to convert tyrosine to DOPA, giving L-DOPA (3,4-dihydroxyphenylalanine). This step is the rate-limiting one in the pathway. The second step is carried out by aromatic L-amino acid decarboxylase, also called DOPA decarboxylase, which removes the carboxyl group from L-DOPA. This decarboxylase depends on the pyridoxal 5′-phosphate cofactor, which is derived from vitamin B6. Tyrosine itself can come from the diet or from phenylalanine, which phenylalanine hydroxylase converts to tyrosine.

The two enzymes are not active everywhere to the same degree. In the brain, dopamine synthesis in dopaminergic terminals requires tyrosine hydroxylase, so the first step is confined largely to dopamine-producing neurons. The decarboxylase is more widely distributed. TH is the rate-limiting enzyme in central dopamine synthesis, while AADC is the rate-limiting enzyme in renal dopamine synthesis. Because the decarboxylase is present in peripheral tissues, orally given L-DOPA is partly converted outside the brain, and dopamine itself does not cross the blood–brain barrier in useful amounts. This is why L-DOPA rather than dopamine is used therapeutically.

Regulation of synthesis

Tyrosine hydroxylase is the main control point. The enzyme is inhibited in a feedback fashion by the catecholamine neurotransmitters. Dopamine binds to the enzyme at the same site that tetrahydrobiopterin occupies, so it competes with that cofactor. Phosphorylation by several kinases at four different serine residues, and dephosphorylation by two phosphatases, modulate its activity. Phosphorylation generally increases activity, so neuronal firing and signalling that activate these kinases raise dopamine output.

Substrate supply also matters. Tyrosine hydroxylase is not normally saturated with tyrosine, so the concentration of tyrosine in the blood and brain can influence how much L-DOPA is made, particularly when demand is high. Experimental depletion of tyrosine reduces brain dopamine in animals, but the effect of tyrosine supplementation in humans is modest and the evidence is mixed. Under therapy, the balance shifts: in patients treated with L-DOPA, the decarboxylase becomes the rate-limiting step of dopamine synthesis.

Breakdown and metabolites

Dopamine action ends mainly through reuptake and enzymatic degradation by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT). MAO first oxidises dopamine to 3,4-dihydroxyphenylacetaldehyde (DOPAL). An aldehyde dehydrogenase then converts this intermediate into 3,4-dihydroxyphenylacetic acid (DOPAC). Some summaries instead describe MAO producing DOPAC directly, so the exact sequence varies by source. COMT, in contrast, O-methylates dopamine to form methoxytyramine. Each of these intermediates can be processed by the other enzyme, and the pathways converge on homovanillic acid (HVA), which is the principal end product of dopamine catabolism. Dopamine metabolism by COMT and MAO-B yields homovanillic acid.

Because these metabolites leave the body through blood, cerebrospinal fluid and urine, they are measured clinically. The concentration of HVA in cerebrospinal fluid roughly corresponds to dopaminergic activity in the brain. HVA is also measured in urine as an indirect index of dopamine turnover, though this reading is only approximate. Urinary HVA is also elevated in neuroblastoma and other neural crest tumours. Norepinephrine is broken down along a similar route, but its primary metabolic by-product, which is readily detectable in the urine, is vanillylmandelic acid.

Storage, release and reuptake at the synapse

Packaging into synaptic vesicles

Once dopamine is synthesized in the cytosol, most of it is loaded into synaptic vesicles by the vesicular monoamine transporter 2 (VMAT2), which is expressed mainly in neurons of the central nervous system. VMAT1 is found mainly in peripheral neuroendocrine cells. VMAT2 belongs to the SLC18 family and works as a proton antiporter: for each monoamine moved into the vesicle, it exchanges two protons out. The energy comes from the vacuolar-type H⁺-ATPase (V-ATPase) in the vesicle membrane, which pumps protons inward and creates both a pH gradient and a membrane potential. Chloride entry through ClC-3 channels helps balance the charge. The result is a steep concentration gradient, so dopamine can accumulate inside vesicles at concentrations far above those in the cytosol.

The acidic vesicle interior also protects dopamine. Dopamine is chemically prone to oxidation, and the cytosolic pH is close to neutral (about 7.1), whereas the vesicle lumen is acidic. Keeping dopamine in vesicles therefore both stores it for later release and removes it from the cytosol, where it would otherwise be degraded by enzymes such as monoamine oxidase. Vesicular packaging is thus a central step in the biochemistry of dopamine. VMAT2 knockout mice fail to load monoamines into vesicles and become severely depleted of stored transmitter, which shows how essential this step is.

Calcium-dependent exocytosis: phasic and tonic release

When an action-potential reaches the axon terminal, voltage-gated calcium entry triggers the fusion of vesicles with the cell-membrane, a process called exocytosis. Dopamine is released in quantal packets, and the amount released depends on the firing pattern of the dopamine neuron. Two modes are usually distinguished.

Phasic release occurs during bursts of spikes. Bursts can briefly saturate the dopamine transporter and push extracellular dopamine into the micromolar range, whereas tonic pacemaker firing produces a steady background that is only around 10 to 20 nanomolar in the extrasynaptic space. Tonic firing is the dominant mode in most dopamine neurons in vivo, but in vivo measurements indicate that the bulk of extracellular dopamine arises from phasic release averaged over time, not from the single spikes of tonic firing. Tonic release is more often associated with presynaptic control and with a motivational background level, while phasic release is thought to carry more of the teaching-like signal that reaches postsynaptic synaptic receptors. These distinctions remain debated, and computational models have produced different estimates of how far released dopamine spreads.

Clearance by the dopamine transporter

The main mechanism for terminating dopamine signalling is reuptake by the dopamine transporter (DAT), a plasma-membrane protein of the SLC6 family. DAT moves dopamine from the extracellular space back into the neuron, using the transmembrane gradients of sodium and chloride. Mechanistically, each transport cycle couples the movement of dopamine to the co-transport of two sodium ions and one chloride ion. Because DAT is so efficient, dopamine typically lingers in the synaptic cleft only briefly. Knockout mice lacking DAT show raised extracellular dopamine and hyperactive locomotion, which illustrates how strongly the transporter controls the signal.

Psychostimulants act on this transporter in different ways. Cocaine binds DAT and blocks the uptake of released dopamine without being transported itself, so the transmitter stays in the cleft longer and the postsynaptic signal is prolonged. Amphetamine is instead a substrate that is taken up by DAT and VMAT2, and it promotes reverse transport of dopamine from the cytoplasm into the extracellular space. Amphetamine can also trigger internalization of DAT from the plasma membrane, which reduces the number of transporters available for uptake. These effects are the subject of ongoing research, and the mechanisms are not yet fully resolved.

Non-synaptic signalling and volume transmission

Dopamine is not confined to classical synapses. Dopamine axons often release transmitter from varicosities that lack a precise postsynaptic specialization, so dopamine acts through diffusion. Volume transmission lets the transmitter spread over distances much greater than the roughly 30 to 40 nanometre width of a classical synapse, reaching receptors at perisynaptic and extrasynaptic sites, sometimes in neighbouring neurons. Dopamine receptors and transporters are largely located outside the synaptic cleft, which is consistent with this non-classical mode of communication. Retinal dopamine cells, like those of the substantia nigra, release dopamine without active zones and act on distant receptors in the same way. Some modelling work suggests that immediately after release diffusion rather than uptake dominates, so dopamine signals may stay fairly localized to their release sites. The overall spatial extent of volume transmission in the brain is still an open empirical question.

Receptors and intracellular signalling

Five receptors in two families

Dopamine acts through five receptor types, all of which belong to the G protein-coupled receptor class. Structural and functional criteria sort them into two families: the D1-like group (D1 and D5) and the D2-like group (D2, D3 and D4). DA exerts its effects through five G protein-coupled receptors that are divided into two families based on structure and biological response. The two families differ in which G proteins they engage. D1-like receptors couple mainly to Gs and Golf, which stimulate adenylyl cyclase, the enzyme that makes cyclic AMP. D2-like receptors couple to Gi and Go, which inhibit that same enzyme. The D1 receptor interacts with the Gs complex to activate adenylyl cyclase, whereas the D2 interacts with Gi to inhibit cAMP production. D2-like receptors are generally regarded as binding dopamine with higher affinity than D1-like receptors, and this difference shapes how each family responds at different extracellular concentrations.

Second messengers and protein phosphorylation

The D1-like cAMP cascade runs through protein kinase A (PKA). The cAMP cascade activates protein kinase A (PKA), which phosphorylates downstream effectors such as dopamine- and cAMP-regulated phosphoprotein, 32 kDa (DARPP-32), ion channels, and transcription factors. DARPP-32 is therefore a central integrator of the two families. D2-like receptors act on the same node from the opposite direction: these receptors are coupled to the pertussis toxin-sensitive, heterotrimeric G proteins G alpha i and G alpha o, which inhibit Adenylyl Cyclase, cAMP production, Protein Kinase A activation, and phosphorylation of DARPP-32 at Thr34. D2-like receptors also engage the phosphatase calcineurin, which removes that phosphate. Beyond cAMP, D1–D2 heteromers (see below) activate phospholipase C and calcium-dependent kinases, and they can increase the expression of brain-derived neurotrophic factor (BDNF). Activation of the Gq-coupled D1-D2 heteromer results in PLC-dependent intracellular calcium release, the activation of CaMKII, and increased expression of BDNF potentially via phosphorylation of MeCP2. In this way, receptor signalling reaches gene expression both through transcription factors and through effects on the proteins that control them.

Distribution across cells

D1-like receptors are widely expressed in the striatum, nucleus accumbens (NAcc), substantia nigra pars reticulata (SNr), and olfactory bulb (OB). D2 receptors show the highest levels in the caudate-putamen, nucleus accumbens and substantia nigra. Both families are present in the nigrostriatal and mesocorticolimbic pathways, although the anatomical distributions of these two receptors overlap in the CNS, yet their quantitative ratios differ significantly in particular anatomical areas. D3 is more restricted: it is found in greater abundance in the limbic regions of the brain, such as the nucleus accumbens.

At the cellular level, D1-like receptors are found postsynaptically on dopamine-receptive cells, while D2-like dopamine receptors are expressed both postsynaptically on dopamine target cells and presynaptically on dopaminergic neurons. Presynaptic D2 receptors act as autoreceptors that regulate the neuron's own release. Because postsynaptic D2 receptors outnumber autoreceptors, the effect of the A1 allele on [11C]raclopride binding at rest would predominantly reflect post-synaptic D2 receptor density. Evidence that astrocytes carry dopamine receptors is more limited. Reviews describe receptor–receptor interactions in these glial cells, including A2A–D2 and D2–oxytocin receptor heteromers, but the possible involvement of these receptors in mosaicism has never been investigated in striatal astrocytes.

Receptor–receptor interactions

Dopamine receptors also form complexes with each other and with receptors for other ligands. These novel heteromeric complexes have functional properties distinct from the component receptors or are able to modulate the canonical signaling and function of the cognate receptors. The D1–D2 heteromer is the best-characterised example. Its first identification came from rat striatum, where it was shown to couple to the Gq/11 protein, a finding that effectively linked dopamine directly to calcium signaling in brain. Its signal is distinct from either receptor acting alone: the activation of Gq by the D1-D2 heterooligomer has been shown to occur in cells expressing both receptors, as well as in striatum, distinct from Gs/olf or Gi/o activation by the D1 and D2 receptor homooligomers, respectively. Physical contact was supported by imaging in brain sections, where a physical interaction between the endogenously expressed D1R and D2R was first shown using quantitative confocal FRET in brain sections in situ.

Other heteromers are antagonistic. The antagonistic A2AR-D2R and A1R-D1R heterodimeric interactions are predominantly seen in the striato-pallidal and striato-nigral neurons, respectively, showing their distinct localization in the basal ganglia. In the A2A–D2 case, the receptor pair shifts D2 signalling: a conformational state of the D2R was induced, which moved away from Gi/o signaling and instead favored β-arrestin2-mediated signaling. Much of this evidence comes from cell culture and brain-tissue studies, and the physiological weight of individual heteromers in intact animals is still being established.

Genetic variation

Variation in receptor genes is linked to differences in receptor density. The most studied variant is the Taq1A polymorphism near the DRD2 and ANKK1 genes, a single-nucleotide polymorphism (rs1800497). Both in vivo and in vitro studies have documented that the minor A1 allele (or T allele) of the Taq1A polymorphism is correlated with regulating the density and availability of dopamine D2 receptor. Positron emission tomography studies in healthy volunteers have reported that the TaqA1 allele is associated with reduced D2/3 BPND at baseline in healthy controls. The picture is not uniform across populations. One study reported opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder. Associations with clinical outcomes, such as increased risk of developing PD compared to A2 homo carriers, have been reported, but these links are based on association studies and do not establish a causal role for receptor density.

Major dopaminergic pathways in the brain

Dopamine-producing neurons are concentrated in a small number of midbrain and hypothalamic nuclei, and their axons project to a limited set of targets. These projections are usually grouped into four main pathways. Two adjacent midbrain structures supply most of them: the substantia nigra pars compacta (SNc) and the ventral tegmental area (VTA). A separate population lies in the hypothalamus. Some accounts add further minor tracts, so the exact count varies between sources.

Nigrostriatal pathway

The nigrostriatal pathway carries dopamine from the compact zone of the substantia nigra to the caudate nucleus and putamen. The substantia nigra is in the midbrain, while the caudate and putamen both sit in the dorsal striatum. Its activity supports motor control. Loss of these neurons in Parkinson's disease is the basis of the characteristic movement symptoms, which are discussed in the motor section.

Mesolimbic pathway

The mesolimbic pathway starts in the VTA and innervates the ventral striatum (nucleus accumbens), the olfactory tubercle, and adjacent limbic regions. Tracing studies also report projections to the amygdala, the hippocampus, and the anterior cingulate cortex, as summarised in a standard table of dopaminergic pathways that lists its function as limbic regulation. The nucleus accumbens lies in the ventromedial part of the striatum, which is why the pathway is closely tied to reward and motivation.

Mesocortical pathway

The mesocortical pathway also arises from the VTA, but its axons terminate on the cerebral cortex. It innervates different regions of the frontal cortex. Its main targets include the prefrontal cortex, and it is linked to cognitive processing, learning, and working memory. Together with the mesolimbic pathway, it forms the mesocorticolimbic system, a term that reflects their shared origin in the VTA.

Tuberoinfundibular pathway

The tuberoinfundibular pathway differs from the other three in that it links the brain to the endocrine system. Dopamine is released from tuberoinfundibular neurons in the external zone of the median eminence and carried through the hypophysial portal vessels to the anterior pituitary. There it inhibits the secretion of prolactin from lactotroph cells. In this case dopamine acts more like a hormone than a classical synaptic transmitter, and the pathway is therefore not directly concerned with movement or reward.

How the circuits connect to the basal ganglia

The nigrostriatal and mesolimbic systems meet in the striatum, which is the main input structure of the basal ganglia. The dorsal striatum receives dopamine from the SNc, while the ventral striatum receives it from the VTA, so the two midbrain sources modulate neighbouring parts of the same circuit. Dopamine acts on both the direct and indirect output pathways of striatal projection neurons, and the balance between them shapes how cortical signals are translated into action. Mesocortical axons reach the frontal cortex, which sends glutamatergic input back to the striatum, creating a loop between cortex and basal ganglia.

Regional differences in receptor expression

Each pathway's response to dopamine depends on which receptors are present in its target region. D1-like receptors (D1 and D5) and D2-like receptors (D2, D3, and D4) are unevenly distributed across the striatum, the prefrontal cortex, and the pituitary. One review notes that D2 receptors are higher in number in the mesolimbic and nigrostriatal pathways, and this distribution is central to how these pathways are interpreted in disease. In the pituitary, the D2 receptor mediates the inhibition of prolactin by tuberoinfundibular dopamine. Dopamine neurons also express D2-type autoreceptors on their own cell bodies and terminals, so each pathway regulates its own output as well as its targets.

Reward prediction, motivation and learning

In the 1980s and 1990s, Wolfram Schultz and colleagues recorded from dopamine neurons in awake macaques performing simple tasks. Early in training, the neurons fired in a brief burst when the monkey received an unexpected juice reward. As the animal learned that a sensory cue reliably preceded the reward, the burst moved earlier in time, to the cue, and the response to the reward itself faded. When an expected reward was omitted, activity dipped below baseline at the moment the reward should have arrived. Hollerman and Schultz (1998) showed that the same neurons also responded to rewards that came at unpredicted times and were suppressed when a predicted reward failed to appear, so they encode errors in both the occurrence and the timing of rewards. Similar reward-prediction signals have since been reported in midbrain dopamine neurons of rodents and humans, and recordings in monkeys have shown that the signal is larger when the animal has just paid a higher effort cost to earn the reward.

Reward prediction error and temporal-difference learning

The reward prediction error (RPE) hypothesis proposes that phasic dopamine signals the difference between the reward received and the reward expected. A positive error (a better-than-expected outcome) increases firing; a negative error (a worse-than-expected outcome) decreases it; and a fully predicted outcome produces no change. This idea links neurobiology to reinforcement learning theory. In the temporal-difference (TD) learning algorithm, the agent updates its value estimates using the error between successive predictions, not only the final outcome. Because the TD error moves backward in time as a cue becomes predictive, a TD model reproduces the shift of dopamine responses from reward to cue that Schultz's group observed. Schultz and colleagues showed that the population response closely matched TD error traces, and the hypothesis has since been used to interpret dopamine signals in a wide range of tasks. Some researchers have argued that dopamine neurons also carry signals that are not explained by RPE alone, such as reward uncertainty or motor-related activity, so the hypothesis is a central framework rather than a complete account.

Wanting versus liking

Dopamine's role in reward was once widely described as producing pleasure. Kent Berridge and Terry Robinson challenged this view with lesion and stimulation studies in rats. In 1989, Berridge and colleagues showed that rats whose nucleus accumbens and dorsal striatum had lost 98–99% of their dopamine stopped seeking and eating food, yet still showed normal facial "liking" reactions when sweet solutions were placed in their mouths. Electrical stimulation that raised dopamine release markedly increased the rats' pursuit of food, but did not increase their liking reactions to it. Peciña and colleagues (2003) later found that hyperdopaminergic mice worked harder for sugar without showing greater liking responses. On this basis, Berridge and Robinson proposed that mesolimbic dopamine mediates "incentive salience", the process by which reward-related cues become attractive and motivating (incentive salience). Hedonic pleasure, by contrast, is thought to depend on small, distributed "hedonic hotspots", including sites within the nucleus accumbens, whose function is less dependent on dopamine. This account is influential but still debated. Critics argue that dopamine also contributes to learning about rewards and that the separation between wanting and liking is less absolute than the theory suggests.

Habits, effort and flexible choice in the nucleus accumbens

Dopamine input to the nucleus accumbens, the ventral part of the striatum that forms part of the basal ganglia, shapes how actions are selected and how they change with experience. Striatal neurons form two main output pathways: the direct pathway, whose cells express D1-type receptors, and the indirect pathway, whose cells express D2-type receptors and adenosine A2A receptors. Yawata and colleagues (2012) used pathway-selective manipulations in mice and found that D1 receptor activation in the direct pathway was needed to acquire reward-based learning, whereas D2 receptor signalling in the indirect pathway was involved in aversive learning. Their work also indicated that the two pathways contribute differently to flexibility when an animal must switch strategies. Recordings and optogenetic experiments in rodents suggest that the indirect pathway is particularly involved in effort-related decisions: stimulating it reduces effort exertion without impairing general movement, whereas stimulating the direct pathway can trigger competing consummatory behaviours. Lesion and pharmacological studies by Salamone and colleagues show that rats with depleted accumbens dopamine shift their choices toward less demanding food-seeking options, indicating that dopamine supports the willingness to work for rewards.

Habit formation is also linked to dopamine. Ahn and Phillips (2007) reported that dopamine efflux in the nucleus accumbens was greater after extended training, when instrumental responding had become habitual, than in early training. Chemogenetic work in rats by Sharpe and colleagues showed that inhibiting ventral tegmental dopamine neurons, or their projections to the nucleus accumbens, weakened the ability of reward-paired cues to drive reward seeking, while leaving some habitual retrieval behaviour intact. These findings suggest that dopamine is important for motivating and directing learned behaviour, and that different pathways and receptor types contribute to how actions are chosen, sustained, and modified.

Motor control and the basal ganglia

Dopamine's best-established motor role lies in the nigrostriatal pathway, which runs from the substantia nigra pars compacta to the dorsal striatum (the caudate nucleus and putamen), a major part of the basal ganglia. Within the striatum, dopamine acts on two populations of medium spiny projection neurons. D1-type receptors, which couple to stimulatory G proteins, tend to facilitate the "direct" pathway that promotes movement, while D2-type receptors, which couple to inhibitory G proteins, act on the "indirect" pathway that suppresses unwanted movement. Dopamine released from dopaminergic neurons therefore biases the balance between these two routes, which is how the nigrostriatal system helps to initiate voluntary movement, keep it going, and scale its vigour. The strongest evidence comes from clinical observation: when this input fails, movement becomes slow and difficult to start rather than simply weak.

Parkinson's disease is characterised by progressive degeneration of dopamine neurons in the substantia nigra, and this loss is widely regarded as the principal cause of its cardinal motor features. Bradykinesia (slowness of movement), rigidity, resting tremor and, in later stages, impaired postural reflexes appear once dopaminergic innervation of the striatum has fallen substantially. Because motor symptoms only emerge after a large fraction of the nigral neurons has been lost, the disease is usually diagnosed late in its course. Non-motor features, including cognitive, psychiatric and autonomic problems, are discussed in other sections of this entry.

Dopamine itself does not cross the blood–brain barrier, so the main replacement strategy uses its precursor levodopa (L-DOPA), which is taken up into the brain and converted to dopamine by aromatic L-amino acid decarboxylase in the remaining neurons. Levodopa is usually given with carbidopa, a decarboxylase inhibitor that does not enter the brain and so reduces peripheral conversion, thereby increasing the amount reaching the brain and lowering nausea and blood-pressure side effects. Levodopa is the most effective symptomatic treatment, but its limitations emerge over time. Benefit from each dose shortens (the "wearing-off" effect), patients may swing unpredictably between mobile "on" and immobile "off" states, and involuntary movements (dyskinesias) appear, often at high plasma levels. A mechanistic account holds that, as dopamine neurons degenerate, the remaining serotonergic and other cells convert levodopa to dopamine and release it without the normal regulated reuptake, producing pulsatile rather than steady stimulation of striatal receptors. Receptor supersensitivity and altered glutamatergic signalling are also implicated, and dyskinesia is generally considered a function of disease duration more than of cumulative dose.

Dopamine agonists are the second major class of symptomatic therapy. These drugs act directly on dopamine receptors, mainly D2-type receptors, and do not require enzymatic conversion. Examples include pramipexole, ropinirole and rotigotine, and apomorphine is used for rescue treatment of off episodes. Agonists were used early in treatment to delay levodopa and its dyskinesias, and they have longer durations of action that can smooth fluctuations. Their drawbacks include somnolence, orthostatic hypotension, hallucinations, and impulse-control disorders such as compulsive gambling or shopping. Because increasing dopaminergic replacement is itself constrained by these side effects, combination regimens must be balanced carefully, and deep brain stimulation is reserved for advanced cases.

Beyond the classic movement deficits, dopamine also contributes to motor learning and movement timing. Striatal dopamine signals are linked to the reinforcement-driven refinement of motor sequences, and the gradual improvement of skilled movements depends in part on dopamine-dependent plasticity at corticostriatal synapses. Patients with Parkinson's disease often show difficulty learning new sequences and estimating or producing intervals of time, which suggests that dopamine helps set the pace and rhythm of action as well as its amplitude. The precise contribution of dopamine to timing, as opposed to general motivation or vigour, remains debated.

Cognition, working memory and synaptic plasticity

Working memory and the inverted-U curve

Dopamine's influence on prefrontal working memory is usually described as an inverted-U function. In rats and monkeys performing working memory tasks, both too little and too much D1-type receptor stimulation in the prefrontal cortex impairs performance. When D1 receptor agents are administered to rats or monkeys performing working memory tasks, an "inverted U" dose/response function is typically observed. Single-neuron recordings in monkeys suggest a mechanism. Low D1 stimulation sharpened spatial tuning by suppressing responses to non-preferred directions, while high stimulation reduced delay-period firing for every direction, which eroded the tuning low levels of D1R stimulation enhance spatial tuning by suppressing responses to nonpreferred directions, whereas high levels reduce delay-related firing for all directions, eroding tuning. These effects are reported to be carried by cyclic AMP signalling in both monkeys and rats These sculpting actions of D1R stimulation are mediated in monkeys and rats by cyclic AMP intracellular signaling.

Human data point in the same direction. In one study, prefrontal D1 receptor binding showed an inverted-U relation with performance on the Wisconsin Card Sorting Test We found a significant "inverted U-shaped" relation between prefrontal D1 receptor binding and performance of the Wisconsin Card Sorting Test. A 2021 meta-analysis reported the inverted quadratic fit was much stronger for prefrontal D1DRs alone, explaining 26% of the variance, compared to prefrontal dopamine alone, explaining 10% of the variance. Across a distributed frontoparietal network in macaques, mid-range dopamine release sustained persistent activity, whereas release that was too low or too high produced only transient responses A mid-range level of dopamine release engaged a distributed pattern of persistent activity throughout these areas, but release that was too low or too high only led to a transient response. The sources reviewed here do not clearly establish that receptor density itself changes in real time with cognitive load; the cited human studies compare receptor binding with performance across individuals.

Attention, flexibility and decisions under uncertainty

Dopamine is generally thought to shape which information the prefrontal cortex holds online, when a rule should be abandoned, and how strongly outcomes are weighted when they are uncertain. The phasic component of the signal is usually linked to prediction error, since dopamine neurons display a short-latency, phasic reward signal indicating the difference between actual and predicted rewards. By contrast, it is distinctly different from dopamine's tonic enabling of numerous behavioral processes. The Wisconsin-test findings above are the main human evidence linking prefrontal receptor levels to set-shifting and flexibility, but the causal chain from receptor state to attentional choice remains incompletely mapped.

Long-term potentiation and depression

Dopamine is a strong modulator of the synaptic changes that underlie learning. In rat prelimbic cortex, the induction of long-term depression (LTD) and long-term potentiation (LTP) of glutamatergic synapses is powerfully modulated by dopamine. Part of the effect on LTD is postsynaptic: enzymatic processes triggered by dopamine receptor activation cooperate with those triggered by glutamate metabotropic receptor activation. Tonic background dopamine appears to act as a gate. One proposal is that it prevents high-frequency synaptic inputs from abnormally inducing LTD and secures the induction of LTP. In that work, this priming occurs through the combined activation of D_1 and D_2 receptors and requires 12–40 min to develop. A biophysical model of prefrontal pyramidal neurons extends this idea. There, dopamine controls the synaptic modification threshold between long-term depression and potentiation, acting through D1 and D2 receptors in a concentration-dependent manner. The in vitro literature is not fully consistent: in vitro experimental results on dopamine-dependent shaping of prefrontal long-term plasticity often appear inconsistent and, altogether, draw a complicated picture.

Striatal plasticity has been studied in parallel. Corticostriatal LTP and LTD might underlie motor-skill learning, cognitive performance and reward mechanisms. Phasic dopamine activity promotes striatal LTP, and the same cellular machinery is thought to contribute to drug-related plasticity, since neuroadaptations leading to addiction involve the same glutamate-dependent cellular mechanisms that enable learning and memory.

Interactions with other neuromodulators

Dopamine acts alongside other transmitters rather than alone. Acetylcholine is one example: acetylcholine seems to be a key mediator of dopamine-dependent striatal plasticity and learning, and dopamine release is strongly modulated by the activation of nicotinic receptors located on dopaminergic nerve terminals in the striatum.

Serotonin appears to have an opposing or permissive role in some tasks. Evidence suggests that pharmacological disruption of serotonin neurotransmission results in a facilitative effect on the processing of mnemonic information by cerebral regions under strong, functional DA modulation, such as the striatum and the PFC, while increased serotonergic signalling appears to have a detrimental effect on cognitive functions integrated in these structures.

Glutamate and GABA are equally important. Interactions among these neurotransmitters, such as dopamine-Glu cross-talk through N-methyl-D-aspartate and dopamine receptors, and GABAergic regulation of dopaminergic activity, are critical for cognitive function. A recent study in nonhuman primates, which simultaneously sampled several transmitters, found that cognitively engaging with the set shifting task was best predicted by GABAergic and cholinergic changes in the PFC, and by dopaminergic and glutamatergic changes in the striatum. Because this line of work is still new, its region-specific patterns should be considered provisional.

Peripheral and hormonal functions

A substantial share of the body's dopamine acts outside the brain, where it helps regulate hormone secretion, kidney salt handling, vascular tone and gut function. Dopamine given intravenously does not cross the blood–brain barrier, so its peripheral actions are also the ones clinicians exploit most directly.

Pituitary and prolactin

Dopamine released from hypothalamic neurons enters the hypophyseal portal circulation and reaches the anterior pituitary, where it binds D2-type receptors on lactotroph cells and suppresses the secretion of prolactin. Because this inhibition is more or less continuous, interrupting it raises circulating prolactin. Dopamine-blocking antipsychotics and prolactin-secreting pituitary tumours (prolactinomas) both cause hyperprolactinaemia, which can present as galactorrhoea, menstrual disturbance or sexual dysfunction. D2 agonists such as bromocriptine and cabergoline lower prolactin and are used to treat these conditions.

Kidney, blood pressure and vascular tone

The kidney contains a local dopamine system. Proximal tubule cells take up circulating L-DOPA and decarboxylate it to dopamine, so much of the renal dopamine is made locally rather than delivered from the brain. Dopamine acting on D1-like receptors in the tubule reduces sodium reabsorption, partly by lowering the activity of the Na⁺/H⁺ exchanger NHE3 and the Na⁺/K⁺-ATPase, which increases sodium excretion when salt intake rises. This natriuretic effect is considered one of the mechanisms that helps keep blood pressure stable. Impaired renal dopamine signalling has been reported in salt-sensitive hypertension. Variants of the GRK4 gene, which encodes a kinase that phosphorylates D1 receptors, reduce receptor function and have been associated with hypertension in some populations, though the link is not uniform across studies.

Dopamine also acts on vascular smooth muscle. D1-like receptors promote vasodilation in renal, mesenteric and coronary beds. Dopamine is additionally released from sympathetic nerve terminals, where presynaptic D2-like receptors inhibit norepinephrine release, providing a local brake on sympathetic vasoconstriction.

Gastrointestinal tract and the enteric nervous system

The gut receives dopamine from the blood and contains dopaminergic neurons within the enteric nervous system. Activation of D2-like receptors on enteric neurons generally slows motility and reduces acetylcholine-dependent contraction, and dopamine has inhibitory effects on several secretory processes in the digestive tract. These actions explain why dopamine antagonists are used clinically to speed gastric emptying. Metoclopramide blocks D2 receptors both peripherally and centrally, whereas domperidone acts mainly in the periphery because it penetrates the brain poorly, which limits its central side effects.

Immune cells and clinical use

Lymphocytes, monocytes, dendritic cells and neutrophils express dopamine receptors and transporters. Reported effects include changes in cytokine production and immune cell migration, but these findings come largely from cell culture and animal work, and the outcomes depend on receptor subtype, cell type and dose.

Intravenous dopamine is used as a vasopressor and inotrope in shock. Its effects are dose-dependent: low infusion rates act mainly on dopamine receptors in renal and splanchnic vessels, intermediate rates stimulate β1-adrenergic receptors in the heart to increase contractility and heart rate, and high rates activate α1-adrenergic receptors to constrict vessels and raise blood pressure. Current sepsis guidelines generally favour norepinephrine as the first-line vasopressor, and dopamine is used less often, partly because of its association with tachyarrhythmias.

Dysregulation and clinical relevance

The dopamine hypothesis of schizophrenia grew out of two pharmacological observations. Amphetamine, which raises synaptic dopamine, can provoke psychotic symptoms even in people without a psychiatric history, and the clinical potency of antipsychotic drugs follows their ability to occupy D2 receptors. The first formulation held that excess dopaminergic transmission underlies psychosis. Later versions, notably the one published by Howes and Kapur in 2009, refined this view. They located the main abnormality in elevated presynaptic dopamine synthesis and release in the associative striatum, and they proposed that reduced dopamine activity in the prefrontal cortex could contribute to negative and cognitive symptoms. PET studies using radiolabelled DOPA and amphetamine challenges support higher striatal dopamine function in patients, although effect sizes vary between studies. The hypothesis has clear limits. A substantial minority of patients do not respond to D2 blockade, common variants in dopamine-related genes show only small associations with risk, and glutamatergic models now compete with it as an explanation.

Dopamine is also implicated in ADHD, but the evidence is more indirect than the pharmacology might suggest. The most effective medications, methylphenidate and amphetamine-type stimulants, act on dopamine: methylphenidate blocks the dopamine and norepinephrine transporters, while amphetamines increase dopamine release. Some imaging studies report lower striatal transporter availability in adults with ADHD, but findings have been inconsistent. Candidate-gene studies of the dopamine transporter and the D4 receptor have produced small associations, many of which have not replicated. Because stimulants also act on noradrenergic systems, a good response to treatment cannot by itself show that dopamine deficiency causes the disorder. The most defensible reading is that dopamine contributes to the reward and motivational deficits seen in some patients, without being a sufficient explanation.

The evidence for dopamine in bipolar disorder and depression is weaker still. Stimulants and dopamine-enhancing agents can trigger manic episodes, which has encouraged the idea that excess dopaminergic signalling contributes to mania. However, the mainstay mood stabilizers lithium and valproate do not act primarily through dopamine. Depressive states, marked by anhedonia, reduced effort and blunted reward responses on neuroimaging, have been linked to reduced dopamine-dependent reward signalling. Bupropion, which inhibits dopamine and norepinephrine reuptake, is used clinically, yet direct evidence that depressed patients have low dopamine levels is limited. Serotonergic and noradrenergic hypotheses have historically received more support. Most of these studies are small and cross-sectional, so they struggle to separate cause from consequence.

Many addictive substances converge on the mesolimbic circuit by raising extracellular dopamine in the nucleus accumbens, but they do so through different mechanisms. Cocaine binds the dopamine transporter and blocks reuptake, so dopamine remains in the synaptic cleft for longer. Amphetamine is taken up through the transporter and disrupts the vesicular pH gradient via VMAT2, so dopamine leaks into the cytoplasm. It then drives reverse transport of dopamine out of the terminal. Nicotine, opioids and alcohol act more indirectly, mainly by changing the firing of ventral tegmental area neurons or their inhibitory inputs. Repeated exposure is associated with lasting adaptations. PET studies in people with stimulant use disorders have reported reduced striatal D2 receptor availability, though whether this is a cause or a consequence remains debated.

Antipsychotic drugs block D2 receptors, and first-generation agents such as haloperidol and chlorpromazine do so with high potency. Because the same receptors operate in the nigrostriatal pathway, their blockade produces extrapyramidal symptoms: parkinsonian rigidity and tremor, akathisia (motor restlessness) and acute dystonia. Long-term treatment can cause tardive dyskinesia, a condition of involuntary movements that is thought to involve receptor supersensitivity, although its mechanism is not fully resolved. Blockade in the tuberoinfundibular pathway removes the normal inhibition of prolactin release, leading to hyperprolactinemia with galactorrhea and sexual dysfunction. Second-generation drugs such as clozapine and risperidone also antagonize serotonin 5-HT2A receptors, which is associated with a lower risk of motor side effects, though these agents carry their own metabolic and cardiovascular concerns.

Discovery, research history and measurement methods

Dopamine was known to chemists for decades before anyone showed it had a role in the brain. Before the late 1950s it was widely regarded as an intermediate in making norepinephrine, with no function of its own. That view changed in Stockholm. In November 1957, Arvid Carlsson and colleagues reported that L-DOPA, the amino acid that dopamine is made from, reversed the akinesia and sedation caused by reserpine in animals. In February 1958 they confirmed dopamine in rabbit brain, and showed that reserpine depleted it while L-DOPA restored it. The behavioural effect tracked the recovery of dopamine rather than noradrenaline or serotonin, which pointed to dopamine depletion as the cause of the immobility. Carlsson then proposed that dopamine acts as a neurotransmitter involved in motor control. The proposal met considerable scepticism at first. His laboratory also mapped dopamine across the brain and found the highest concentrations in the striatum, and he developed a sensitive fluorescence method to measure it.

Carlsson's work was recognised in 2000, when he shared the Nobel Prize in Physiology or Medicine with Paul Greengard and Eric Kandel "for their discoveries concerning signal transduction in the nervous system." The Nobel Assembly cited Carlsson for showing that dopamine is a transmitter in the brain and that it is important for controlling movement. Greengard's share concerned how dopamine and other transmitters act through slow synaptic transmission, based on the phosphorylation of proteins such as ion channels, with effects lasting from seconds to hours. This line of work linked the discovery of dopamine as a transmitter to the intracellular signalling described in synapses and the wider Nobel tradition in neuroscience.

Measuring dopamine in living tissue has been a long-running technical challenge, and each major method trades off spatial resolution, time resolution and specificity. In vivo microdialysis has been used for more than forty years to track extracellular dopamine during drug exposure, but the probes are relatively large and sampling is slow, which makes it hard to link fast changes to specific behaviours. Fast-scan cyclic voltammetry (FSCV) addresses these limits. A carbon-fibre microelectrode is driven with a rapid triangular voltage waveform, for example ramping between about −0.4 and +1.0 V at 300 V/s and repeated at 10 Hz; the oxidation current of dopamine is then isolated by subtracting the background charging current. FSCV resolves release on a millisecond timescale, but its signals for dopamine, serotonin and norepinephrine overlap, so careful calibration and pharmacological controls are needed to attribute a signal to dopamine.

Positron emission tomography (PET) allows dopamine receptors and transporters to be imaged in humans. Radiolabelled ligands such as [11C]raclopride bind to D2-type receptors, and because endogenous dopamine competes for the same sites, changes in the tracer signal can reflect changes in dopamine release. Recent modelling suggests that these fluctuations can reveal dopamine release at the scale of about a minute, which has been validated against FSCV in mice during chemogenetic activation of dopamine neurons. PET is non-invasive but provides slow, indirect measures and cannot resolve individual synapses.

Genetic tools have transformed the ability to test what dopamine neurons do, because the dopamine population is small and anatomically intermingled with other cell types. optogenetics uses light-sensitive ion channels expressed in defined cells to activate or silence them within milliseconds, and it has been used to show that stimulating dopamine neurons is sufficient to produce reinforcement-like responses. chemogenetics, which relies on engineered receptors activated by otherwise inert drugs, offers slower but longer-lasting control that suits behavioural experiments. Cell-type-specific genetic access, typically through promoters or Cre-driver lines targeting genes for dopamine synthesis, allows researchers to separate dopamine neurons from neighbouring cells and to compare the projections of different subpopulations.

Several questions remain open. Researchers still debate how dopamine signals encode effort costs, the uncertainty of outcomes, and social information such as the behaviour or intentions of others. Part of the difficulty is methodological: phasic bursts, slower tonic levels and volume-transmitted signals are measured with different tools that have different sensitivities, and it is not always clear how a signal recorded in one way maps onto the others. Progress will depend on combining these measurement methods with cell-type-specific manipulations in behaving animals.

References

1. Tyrosine Hydroxylase and Regulation of Dopamine Synthesis - PMCpmc.ncbi.nlm.nih.gov
2. Treatment of prostate cancer with DDC inhibitorimage-ppubs.uspto.gov
3. Dopamine Metabolism - an overviewsciencedirect.com
4. Tyrosine hydroxylase and regulation of dopamine synthesis - PubMedpubmed.ncbi.nlm.nih.gov
5. Trait: Dopamine Metabolism (MAO)fitnessgenes.com
6. Catecholamine Metabolism - an overviewsciencedirect.com
7. Dopamine Metabolism - an overviewsciencedirect.com
8. Homovanillic Acid - 3200 Metabolomix+ - FMV Urine - Lab Results explainedhealthmatters.io
9. Tyrosine Decarboxylase - an overviewsciencedirect.com
10. Homovanillic Acid (HVA): Optimal Levels, Reference Ranges & Dopamine Pathway Interpretationlamkinclinic.com
11. Drug inhibition and substrate transport mechanisms of human VMAT2nature.com
12. Vesicular Monoamine Transporter - an overviewsciencedirect.com
13. Packaging monoamine neurotransmittersnature.com
14. Structural insights into substrate transport and drug inhibition of the human vesicular monoamine transporter 2 (VMAT2) - Wu - 2025 - The FEBS Journal - Wiley Online Libraryfebs.onlinelibrary.wiley.com
15. pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov
16. Trafficking of dopamine transporters in psychostimulant actions - ScienceDirectsciencedirect.com
17. Cocaine-regulated trafficking of dopamine transporters in cultured neurons revealed by a pH sensitive reporter - ScienceDirectsciencedirect.com
18. A novel pH-sensitive reporter reveals the cocaine-regulated trafficking of dopamine transporters in neuronal processesbiorxiv.org
19. Amphetamine-induced loss of human dopamine transporter activity: An internalization-dependent and cocaine-sensitive mechanismpnas.org
20. Insights into the Modulation of Dopamine Transporter Function by Amphetamine, Orphenadrine, and Cocaine Bindingncbi.nlm.nih.gov
21. Cocaine-insensitive dopamine transporters with intact substrate transport produced by self-administration - PMCpmc.ncbi.nlm.nih.gov
22. 5. Dopamine release (tonic, phasic) and encoding. - ADxS.orgadxs.org
23. Tonic & phasic dopamine: ADHD explanation at the neurotransmitter level - ADxS.orgadxs.org
24. Behavioral/Systems/Cognitive Influence of Phasic and Tonic Dopamine Release onjneurosci.org
25. Extrasynaptic Release of Dopamine and Volume Transmission in the Retinalink.springer.com
26. Dopamine release, diffusion and uptake: A computational model for synaptic and volume transmissionjournals.plos.org
27. Computational models of dopamine release measured by fast scan cyclic voltammetry in vivoncbi.nlm.nih.gov
28. Redefining dopaminergic synapses beyond the classical paradigm - ScienceDirectsciencedirect.com
29. A R T I C L E S 968 VOLUME 6behavioralhealth2000.com
30. Dopamine D2-Like Receptor Family Signaling Pathwaysrndsystems.com
31. Molecular Biology of the Dopamine Receptor Subtypes - ACNPacnp.org
32. D1-Like Receptor - an overviewsciencedirect.com
33. Heteromeric Dopamine Receptor Signaling Complexes: Emerging Neurobiology and Disease Relevancenature.com
34. Dopamine Receptor D1 - an overviewsciencedirect.com
35. Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereofimage-ppubs.uspto.gov
36. Deuterated organic compounds and uses thereofimage-ppubs.uspto.gov
37. DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorderacademic.oup.com
38. Control of Dopamine Signal in High-Order Receptor Complex on Striatal Astrocytesncbi.nlm.nih.gov
39. Dopamine receptor heteromeric complexes and their emerging functions - ScienceDirectsciencedirect.com
40. A Novel Dopamine Receptor Signaling Unit in Brain: Heterooligomers of D1 And D2 Dopamine Receptorsncbi.nlm.nih.gov
41. Heteromerization of dopaminergic receptors in the brain: Pharmacological implications - ScienceDirectsciencedirect.com
42. Diversity and Bias through Receptor–Receptor Interactions in GPCR Heteroreceptor Complexes. Focus on Examples from Dopamine D2 Receptor Heteromerizationncbi.nlm.nih.gov
43. The significant association of Taq1A genotypes in DRD2/ANKK1 with smoking cessation in a large-scale meta-analysis of Caucasian populationsnature.com
44. Genetic variation and dopamine D2 receptor availability: a systematic review and meta-analysis of human in vivo molecular imaging studiesnature.com
45. DRD2 Taq1A Polymorphism-Related Brain Volume Changes in Parkinson's Disease: Voxel-Based Morphometryncbi.nlm.nih.gov
46. The DRD2 Taq1A polymorphism moderates the effect of PTSD symptom severity on the left hippocampal CA3 volume: a pilot studylink.springer.com
47. Dopaminergic pathwaysen.wikipedia.org
48. Tuberoinfundibular Pathway - an overviewsciencedirect.com
49. Current Review of the Function and Regulation of Tuberoinfundibular Dopamine Neuronsncbi.nlm.nih.gov
50. Dopaminergic pathways in the Brain: (A) meso-corical pathway transmits...researchgate.net
51. Mesolimbic Pathway - an overviewsciencedirect.com
52. Understanding dopamine and reinforcement learning: The dopamine reward prediction error hypothesispnas.org
53. Discovering Dopamine’s Role in Reward Prediction Errorbrainfacts.org
54. Wolfram Schultzen.wikipedia.org
55. B a s i c r e s e a r c h Dopamine reward prediction error codingpages.ucsd.edu
56. The cost of obtaining rewards enhances the reward prediction error signal of midbrain dopamine neuronsncbi.nlm.nih.gov
57. Dopamine neurons report and error in the temporal ...hms.harvard.edu
58. MULTIPLE REWARD SIGNALS IN THE BRAIN Wolfram Schultzits.caltech.edu
59. The debate over dopamine’s role in reward: the case for incentive salience - Psychopharmacologylink.springer.com
60. Liking, Wanting, and the Incentive-Sensitization Theory of Addictionsites.lsa.umich.edu
61. The Incentive-Sensitization Theory of Addiction 30 Years Onsites.lsa.umich.edu
62. Liking, Wanting, and the Incentive-Sensitization Theory of ...psycnet.apa.org
63. Why Dopamine Doesn’t Mean Pleasure: The Real Neuroscience Behind Wanting vs. Likingmedium.com
64. Kent Berridge on Dopamine, Addiction, and Neuroscience - Hear This Ideahearthisidea.com
65. Pathway-specific modulation of nucleus accumbens in reward and aversive behavior via selective transmitter receptorspnas.org
66. Pathway-specific control of reward learning and its flexibility via selective dopamine receptors in the nucleus accumbenspnas.org
67. A2A-positive neurons in the nucleus accumbens core regulate effort exertionbiorxiv.org
68. Mesolimbic dopamine projections mediate cue-motivated reward seeking but not reward retrieval in ratsncbi.nlm.nih.gov
69. (PDF) Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits (Berl)researchgate.net
70. Dopamine efflux in the nucleus accumbens during within-session extinction, outcome-dependent, and habit-based instrumental responding for food rewardlink.springer.com
71. Nucleus accumbens neurotransmission and effort-related choice behavior in food motivation: Effects of drugs acting on dopamine, adenosine, and muscarinic acetylcholine receptors - ScienceDirectsciencedirect.com
72. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease - PubMedpubmed.ncbi.nlm.nih.gov
73. Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts - PubMedpubmed.ncbi.nlm.nih.gov
74. Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidencencbi.nlm.nih.gov
75. Levodopa-induced dyskinesia in Parkinson’s disease: an updated review of pharmacological treatmentsncbi.nlm.nih.gov
76. The acute brain response to levodopa heralds dyskinesias in Parkinson diseasencbi.nlm.nih.gov
77. Dopamine D3 Receptor Ligand Suppresses the Expression of Levodopa-Induced Dyskinesia in Nonhuman Primate Model of Parkinson’s Diseasebiorxiv.org
78. Combination preparations comprising bifeprunox and a dopamine agonistimage-ppubs.uspto.gov
79. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopaimage-ppubs.uspto.gov
80. Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progressionlink.springer.com
81. D1 dopamine receptors in the mouse prefrontal cortex: Immunocytochemical and cognitive neuropharmacological analyses - PubMedpubmed.ncbi.nlm.nih.gov
82. Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AFT. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci 10: 376-384researchgate.net
83. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory - University of Texas Southwestern Medical Centerutsouthwestern.elsevierpure.com
84. Roles of hippocampal and prefrontal dopamine D1 and D2 receptors in human neurocognitive functions - ScienceDirectsciencedirect.com
85. Quantifying the inverted U: A meta-analysis of prefrontal dopamine, D1-receptors, and working memory - PMCpmc.ncbi.nlm.nih.gov
86. A dopamine gradient controls access to distributed working memory in the large-scale monkey cortex - ScienceDirectsciencedirect.com
87. Long-term potentiation in rat prefrontal slices facilitated by phased application of dopamine - ScienceDirectsciencedirect.com
88. Dopaminergic Modulation of Long-term Synaptic Plasticity in Rat Prefrontal Neuronsacademic.oup.com
89. The Presence of Background Dopamine Signal Converts Long-Term Synaptic Depression to Potentiation in Rat Prefrontal Cortexjneurosci.org
90. pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov
91. Dopaminergic Control of Long-Term Depression/Long-Term Potentiation Threshold in Prefrontal Cortexjneurosci.org
92. Dopamine-mediated regulation of corticostriatal synaptic plasticity - ScienceDirectsciencedirect.com
93. Psychomotor stimulants and neuronal plasticity - PubMedpubmed.ncbi.nlm.nih.gov
94. Serotonin/dopamine interaction in learning - PubMedpubmed.ncbi.nlm.nih.gov
95. Dopamine, glutamate, and gamma-aminobutyric acid: Key hubs in neurotransmitters, signal transduction, and cognitive dysfunction - PubMedpubmed.ncbi.nlm.nih.gov
96. Cognitive engagement induces area-specific fingerprints of dopamine, acetylcholine, serotonin, glutamate and GABA in prefrontal cortex and striatum - PMCpmc.ncbi.nlm.nih.gov
97. Dopaminergic Neurons: Basic Aspectslink.springer.com
98. Four pioneers of L‐dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr - Lees - 2015 - Movement Disorders - Wiley Online Librarymovementdisorders.onlinelibrary.wiley.com
99. DOPA - an overviewsciencedirect.com
100. Laureates of the Japan Prizejapanprize.jp
101. The Nobel Prize in Physiology or Medicine 2000 - Press release - NobelPrize.orgnobelprize.org
102. 2000 Nobel goes to Arvid Carlsson, Paul Greengard and Eric Kandelthe-scientist.com
103. Fifty years of dopamine research: Trends in Neurosciencescell.com
104. Paul Greengarden.wikipedia.org
105. Rapid Dopamine Release in Freely Moving Rats - Electrochemical Methods for Neuroscience - NCBI Bookshelfncbi.nlm.nih.gov
106. Enhanced Dopamine Sensitivity Using Steered Fast-Scan Cyclic Voltammetrypubs.acs.org
107. Fast Scan Cyclic Voltammetry to Assess Dopamine Function: From Circuits to Behaviorexperiments.springernature.com
108. Time-dependent assessment of stimulus-evoked regional dopamine releasencbi.nlm.nih.gov
109. Cocaine-Induced Changes in Tonic Dopamine Concentrations Measured Using Multiple-Cyclic Square Wave Voltammetry in vivoncbi.nlm.nih.gov